Xianglai Xu
5PUBLICATIONS
6CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Mar 28, 2024
Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.Jiajun Wang, Sihong Zhang, Ying Wang
|Jun 09, 2023
The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.Jiajun Wang, Sihong Zhang, Ying Wang
|Apr 09, 2023
HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma.Xianglai Xu, Sihong Zhang, Ying Wang
|Dec 14, 2022
Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expression.Xianglai Xu, Ying Wang, Zhaoyi Chen
|Nov 04, 2021
Exploration of Prognostic Biomarkers of Muscle-Invasive Bladder Cancer (MIBC) by Bioinformatics.Xianglai Xu, Yelin Wang, Sihong Zhang
Pageof 1
